Finkelstein Thompson LLP Announces Investigation of BioClinica, Inc.

  Finkelstein Thompson LLP Announces Investigation of BioClinica, Inc.

Business Wire

WASHINGTON -- January 30, 2013

The law firm Finkelstein Thompson LLP is investigating potential claims on
behalf of shareholders of BioClinica, Inc. (NASDAQ: BIOC) (“BioClinica” or
“the Company”), concerning the proposed acquisition of the Company by JLL
Partners, Inc. Under the terms of the transaction, BioClinica shareholders
would receive $7.25 per share in cash in a tender offer worth approximately
$124 million.

The investigation is focused on the potential unfairness of the consideration
to shareholders, the process by which the Company’s Board of Directors
considered the transaction, and potential conflicts of interest among
BioClinica‘s Board members.

If you are interested in discussing your rights as a BioClinica shareholder,
or have information relating to this investigation, please contact Finkelstein
Thompson’s Washington, DC offices at (202)-337-8000 or by email at

Finkelstein Thompson LLP has spent over three decades delivering outstanding
representation to institutional and individual clients in financial
litigation, and has been appointed as lead or co-counsel in dozens of
shareholder class actions. Indeed, the firm has served in leadership roles in
cases that have recovered over $1 billion for investors and consumers. To
learn more about Finkelstein Thompson LLP, please visit our website at Attorney advising. Prior results do not guarantee
similar outcomes.


Finkelstein Thompson LLP
Rosalee Thomas, (202)-337-8000
Press spacebar to pause and continue. Press esc to stop.